Literature DB >> 17264872

The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years.

G S Markowitz1, V D D'Agati.   

Abstract

The 2003 International Society of Nephrology (ISN)/Renal Pathology Society (RPS) Classification of lupus nephritis (LN) was designed to eliminate ambiguities and standardize definitions. Major changes from the 1982 Modified WHO Classification include the elimination of the normal biopsy category and the subcategories of membranous Class V, the introduction of sharper distinctions between the classes, and the addition of subcategories within diffuse LN (class IV) for predominantly segmental (LN IV-S) and global (LN IV-G) lesions. It stipulates that sclerotic glomeruli owing to scarred LN should be taken into account when assessing the percentage of glomeruli affected by LN. Since its publication, the ISN/RPS classification has been used successfully in a number of clinical-pathologic studies. Several studies addressing the relationship between LN IV-S and LN IV-G have failed to identify a significantly worse outcome in IV-S than IV-G, although there were some differences in presenting clinical and pathologic features. Importantly, the ISN/RPS classification has achieved its goal of improved interobserver reproducibility. Its use has increased the percentage of LN biopsies meeting criteria for class IV. As it gains widespread acceptance, the ISN/RPS classification is already providing a standardized approach to renal biopsy interpretation needed to compare outcome data across centers.

Entities:  

Mesh:

Year:  2007        PMID: 17264872     DOI: 10.1038/sj.ki.5002118

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  32 in total

1.  Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes.

Authors:  Catharina M Haring; Anke Rietveld; Jan A J G van den Brand; Jo H M Berden
Journal:  J Am Soc Nephrol       Date:  2011-10-27       Impact factor: 10.121

2.  American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.

Authors:  Bevra H Hahn; Maureen A McMahon; Alan Wilkinson; W Dean Wallace; David I Daikh; John D Fitzgerald; George A Karpouzas; Joan T Merrill; Daniel J Wallace; Jinoos Yazdany; Rosalind Ramsey-Goldman; Karandeep Singh; Mazdak Khalighi; Soo-In Choi; Maneesh Gogia; Suzanne Kafaja; Mohammad Kamgar; Christine Lau; William J Martin; Sefali Parikh; Justin Peng; Anjay Rastogi; Weiling Chen; Jennifer M Grossman
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-06       Impact factor: 4.794

3.  Revised ISN/RPS 2018 classification of lupus renal pathology predict clinical remission.

Authors:  Kornwipa Krassanairawiwong; Mongkon Charoenpitakchai; Ouppatham Supasyndh; Bancha Satirapoj
Journal:  Int Urol Nephrol       Date:  2021-03-08       Impact factor: 2.370

Review 4.  Redefining lupus nephritis: clinical implications of pathophysiologic subtypes.

Authors:  Feng Yu; Mark Haas; Richard Glassock; Ming-Hui Zhao
Journal:  Nat Rev Nephrol       Date:  2017-07-03       Impact factor: 28.314

5.  Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa.

Authors:  L B Lewandowski; L E Schanberg; N Thielman; A Phuti; A A Kalla; I Okpechi; P Nourse; P Gajjar; G Faller; P Ambaram; H Reuter; G Spittal; C Scott
Journal:  Lupus       Date:  2016-08-19       Impact factor: 2.911

Review 6.  Recent advances in the treatment of lupus nephritis.

Authors:  Keiko Uchida; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2011-11-08       Impact factor: 2.801

7.  Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis.

Authors:  Stephen D Marks; Vanita Shah; Clarissa Pilkington; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2010-08-05       Impact factor: 3.714

Review 8.  Treatment of proliferative lupus nephritis: a slowly changing landscape.

Authors:  Vladimir Tesar; Zdenka Hruskova
Journal:  Nat Rev Nephrol       Date:  2010-12-21       Impact factor: 28.314

9.  Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up.

Authors:  Lorenza Maria Argolini; Giulia Frontini; Elena Elefante; Francesca Saccon; Valentina Binda; Chiara Tani; Isabella Scotti; Linda Carli; Mariele Gatto; Ciro Esposito; Maria Gerosa; Roberto Caporali; Andrea Doria; Piergiorgio Messa; Marta Mosca; Gabriella Moroni
Journal:  J Nephrol       Date:  2020-05-27       Impact factor: 3.902

Review 10.  Insights into the epidemiology and management of lupus nephritis from the US rheumatologist's perspective.

Authors:  Paul J Hoover; Karen H Costenbader
Journal:  Kidney Int       Date:  2016-06-22       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.